CHIP is associated with a 0.5–1% risk of progression to a non-plasma-cell hematologic neoplasm, in particular myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)6–8, a situation analogous to monoclonal gammopathy of undetermined significance (MGUS). The gene discussed is STUB1; the disease is myelodysplastic syndrome.